利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.023 秒)

    PROCESS FOR THE PURIFICATION OF SUBSTITUTED BENZOXAZOLE COMPOUNDS
    5.
    发明公开
    PROCESS FOR THE PURIFICATION OF SUBSTITUTED BENZOXAZOLE COMPOUNDS 审中-公开
    清洗过程取代恶唑CONNECTIONS

    公开(公告)号：EP1856068A1

    公开(公告)日：2007-11-21

    申请号：EP06737106.2

    申请日：2006-03-06

    申请人： Wyeth, A Corporation of the State of Delaware

    发明人： IERA, Silvio

    IPC分类号： C07D263/56

    CPC分类号： C07D263/57 ,  C07D263/42

    摘要： The present invention provides processes for the purification of substituted benzoxazole compounds of formla (I), and in particular 2-(3-fluoro-4-hydroxy-phenyl)-7-vinyl- benzooxazol-5-ol. The processes include recrystallizing the compound from a solution comprising acetone and acetonitrile; treating the crude purified product with a clarifying agent in a solution comprising ethyl acetate, and precipitating or triturating the compound from a mixed solvent system.

    New treatments using phenethylamine derivatives
    6.
    发明公开
    New treatments using phenethylamine derivatives 无效
    Neue Behandlungsmethoden durch Verwendung von Phenethylaminderivaten

    公开(公告)号：EP1738753A2

    公开(公告)日：2007-01-03

    申请号：EP06017469.5

    申请日：1994-06-13

    申请人： Wyeth, A Corporation of the State of Delaware

    发明人： Rudolph, Richard Leslie ,  Derivan, Albert Thomas ,  Muth, Eric Anthony ,  Upton, Gertrude Virginia

    IPC分类号： A61K31/135 ,  A61P3/04 ,  A61P25/22 ,  A61P25/18 ,  A61P25/26

    CPC分类号： A61K31/137 ,  A61K31/135

    摘要： This invention provides use of a following compound (in particular venlafaxine) to prepare a medicament for treating obesity, post-traumatic stress disorder, late luteal phase disphoric disorder (premenstrual syndrome), attention deficit disorder, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa or Shy Drager Syndrome. The compound is a hydroxycycloalkanephenethyl amine of the following structural formula:

    in which A is a moiety of the formula

    where
    the dotted line represents optional unsaturation;
    R 1 is hydrogen or alkyl;
    R 2 is alkyl;
    R 4 is hydrogen, alkyl, formyl, or alkanoyl;
    R 5 and R 6 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halo, trifluoromethyl, or taken together, methylene dioxy;
    R 7 is hydrogen or alkyl; and
    n is 0, 1, 2, 3, or 4;

    or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明提供以下化合物（特别是文拉法辛）用于制备用于治疗肥胖症，创伤后应激障碍，晚黄体期畸形障碍（经前期综合征），注意缺陷障碍，伴有和不伴有多动症的药物，Gilles de la Tourette 综合征，神经性贪食症或Shy Drager综合征。 该化合物是具有以下结构式的羟基环烷基苯乙胺：其中A是下式的部分，其中虚线表示任选的不饱和度; R 1是氢或烷基; R 2是烷基; R 4是氢，烷基，甲酰基或烷酰基; R 5和R 6独立地是氢，羟基，烷基，烷氧基，烷酰氧基，氰基，硝基，烷基巯基，氨基，烷基氨基，二烷基氨基，烷酰氨基，卤素，三氟甲基，或一起形成亚甲基二氧基; R 7是氢或烷基; 且n为0,1,2,3或4; 或其药学上可接受的盐。